A randomized double-blind placebo-controlled Phase 1 study of NIDO-361 in healthy male subjects
Latest Information Update: 06 Nov 2023
At a glance
- Drugs NIDO-361 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 06 Nov 2023 New trial record
- 05 Nov 2023 According to Nido Biosciences media release, data from the study were presented at the 2023 International Kennedys Disease Patient Conference in London, November 4-5.
- 05 Nov 2023 Results presented in the Nido Biosciences Media Release